Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: HIV

Kaletra® (lopinavir and ritonavir) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Kaletra. For the treatment of HIV-1 infection

Intelence® (etravirine) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Intelence. For the treatment of HIV-1 infection in treatment-experienced patients

Cabenuva (cabotegravir and rilpivirine extended-release injectable suspension)

Approval Date: Jan 2021

Note: New Product

A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month

Norvir® (ritonavir) capsules

Approval Date: Dec 2020

Note: First-Time Generic

Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection

Medication Name

Approval Date

Category

Description

Kaletra® (lopinavir and ritonavir) tablets

Jun 2021

This is the first time a generic has been approved for Kaletra. For the treatment of HIV-1 infection

Note: First-Time Generic

Intelence® (etravirine) tablets

Jun 2021

This is the first time a generic has been approved for Intelence. For the treatment of HIV-1 infection in treatment-experienced patients

Note: First-Time Generic

Cabenuva (cabotegravir and rilpivirine extended-release injectable suspension)

Jan 2021

A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month

Note: New Product

Norvir® (ritonavir) capsules

Dec 2020

Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection

Note: First-Time Generic